Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.89 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796892 | 0.94 | MAPT (0.79) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL5054312 | 0.94 | MAPT (0.85) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL1951546 | 0.94 | MAPT (1.00) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL5400568 | 0.93 | MAPT (0.77) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL6539224 | 0.93 | MAPT (0.90) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL12921583 | 0.93 | MAPT (0.77) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL7937774 | 0.92 | MAPT (0.82) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL2088837 | 0.91 | MAPT (0.79) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL223429 | 0.91 | MAPT (0.79) | MAPTRAB9ACA1CA2L3MBTL1 | |
| SCHEMBL15693338 | 0.91 | MAPT (0.79) | MAPTRAB9ACA1CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371808-A1 | Process for preparing dronedarone | Ratiopharm GmbH (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050049302-A1 | Process for the preparation of dronedarone | ISP INVESTMENTS LLC | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049302-A1 | Process for the preparation of dronedarone | CACNA1C, CACNA1A, KCNH1 | MAPT 3576/4885RAB9A 71/4885CA1 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.